10:52 AM EST, 02/05/2025 (MT Newswires) -- Valneva (VALN) secured marketing authorization in the UK for its Ixchiq vaccine for chikungunya, a mosquito-borne viral disease.

The vaccine, manufactured at the company's leading production site in Livingston, Scotland, got the approval from the Medicines and Healthcare products Regulatory Agency,

The single-dose vaccine is for active immunization for the prevention of disease caused by the chikungunya virus in people 18 years of age and older, Valneva said Wednesday in a statement.

The vaccine is approved in the US, Europe and Canada in adults, and Valneva expects to get marketing approval in Brazil in Q1.

Valneva submitted label extension applications in the US, Europe and Canada to possibly extend the use of Ixchiq to adolescents aged 12 to 17 years and plans to submit a label extension application in the UK.

The company's shares rose 14% in recent Wednesday trading.

Price: 6.43, Change: +0.82, Percent Change: +14.69